Ravulizumab (C5) 抗体, 单克隆-Ravulizumab (C5) Antibody, Monoclonal代理/参数/厂家-一抗-艾美捷科技有限公司

PRODUCT CENTER

一抗

产品中心

当前位置：首页 > 产品中心 > 免疫学产品 > 一抗

背景资料: Ravulizumab is considered a long-acting complement 5 (C5) inhibitor that has been undergoing clinical trials for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) as of 4 February, 2016. A drug similar to ravulizumab (ALXN1210), called eculizumab, is currently approved for the treatment of PNH in 46 countries under the brand name Soliris®. Ravulizumab is considered by Alexion Pharmaceuticals Inc. to be a "next-generation" eculizumab molecule. Ravulizumab was subsequently approved by the US FDA in December of 2018 for a variety of beneficial characteristics that make it an advanced, next-generation agent in comparison to eculizumab. In particular, ravulizumab is currently the first and only long-acting C5 complement inhibitor that can be administered every eight weeks for the treatment of adult patients with PNH whereas eculizumab is a bi-weekly treatment,Label. Moreover, virtually all of the phase 3 trial results for ravulizumab have demonstrated the equivalent efficacy and safety established by eculizumab and that patients transition safely and effectively from using eculizumab to ravulizumab. Subsequently, whereas PNH patients may have needed to previously plan their lives rather strictly around the bi-weekly infusion administrations of eculizumab, with ravulizumab such patients can find a more relaxed dosing schedule of only six or seven infusions over an entire year,Label.

其他: ProSci Incorporated于1998年成立于美国加州圣地亚哥市,从事抗体等科研试剂的研发、生产和销售。产品涵盖了细胞凋亡、信号转导、免疫、肿瘤、细胞生物、神经生物、传染病等领域。ProSci拥有超过30000种单克隆抗体和多克隆抗体。ProSci的抗体大都经免疫亲和层析纯化,具有高纯度、高亲和力、特异性强等特点,所有的ProSci抗体都经过了严格的验证测试和质量控制,已保证高质量的产品。此外,ProSci还提供标记二抗,重组蛋白,细胞和组织裂解液,细胞涂片,组织切片,多肽等产品与抗体配套使用。